




INTERLACE





INTERLACE



Eligibility criteria summary

- All patients suitable for CRT, FIGO IB1 with +ve nodes-IVA unless:
 - Nodes above aortic bifurcation
 - Disease involves lower third of vagina (FIGO IIIA)

IMRT permitted


Recently received ethical approval for redesign of PIS and inclusion of a short series of patient accessible video links (via PIS) explaining the trial and featuring INTERLACE patient interviews.



INTERLACE



INTERLACE Trial - Total Monthly Accrual





INTERLACE



Current status

Target recruitment – **770**

Accrual to date (UK and Mexico) – **172**

Number of sites open - **30**

- GICOM (Mexico) – 21 patients recruited since opening in Feb 2016

- MaNGO (Italy) – 5 sites in setup



INTERLACE



Contacts:

Chief Investigator – Dr Mary McCormack
mary.mccormack@uclh.nhs.uk

RTQA – Yatman Tsang yatmantsang@nhs.net

General Enquiries – ctc.interlace@ucl.ac.uk